Company profile: Feldan Therapeutics
1.1 - Company Overview
Company description
- Provider of a patented peptide-based technology platform for delivering therapeutic compounds into cells, including the Feldan Shuttle, and FLD-103, an intralesional treatment for basal cell carcinoma that targets BCC cells by disrupting an intracellular component involved in the disease’s pathophysiology.
Products and services
- Patented peptide-based technology platform: architects a patented peptide-based platform enabling delivery of therapeutic compounds into cells to facilitate development of treatments targeting intracellular components
- Feldan Shuttle: engineers peptide-based, custom-engineered transport into cells, delivering therapeutic compounds intracellularly to enable development of treatments targeting intracellular components
- FLD-103: produces an intralesional treatment for basal cell carcinoma that targets BCC cells by disrupting an intracellular component involved in the disease’s pathophysiology
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Feldan Therapeutics
RNAissance Ag
HQ: United States
Website
- Description: Provider of ribonucleic acid and RNAi products, offering innovative technology for large-scale fermentation-based production of exogenous RNAi, addressing mass production challenges and enabling farmers to protect and improve crops and cattle.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full RNAissance Ag company profile →
Synlab
HQ: Germany
Website
- Description: Provider of laboratory diagnostics for human and veterinary medicine and environmental analysis services. Delivers wide-ranging laboratory testing, specialty and genetic testing (including preimplantation), supported by 2,000+ medical experts across 30+ countries and 2,000+ blood collection points. Also focuses on medical supplies trade, clinical trials, and consulting.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Synlab company profile →
Candel Therapeutics
HQ: United States
Website
- Description: Provider of viral cancer immunotherapies and a discovery platform. Offers CAN-2409, a genetically modified adenovirus to elicit individualized anti-tumor responses in prostate, pancreatic, and lung cancers; CAN-3110, a modified herpes simplex virus for recurrent high-grade glioma; enLIGHTEN Discovery Platform to create HSV-based viral immunotherapies for solid tumors; conducts clinical trials for prostate, brain, pancreatic, and lung cancers and provides an expanded access policy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Candel Therapeutics company profile →
Precision BioSciences
HQ: United States
Website
- Description: Provider of ARCUS genome editing technology using sequence-specific nucleases to modify DNA in living cells and tissues, a Manufacturing Center for Advanced Therapeutics for production of advanced therapies, PBGENE-HBV targeting chronic hepatitis B, and partnerships for in vivo gene editing and ex vivo CAR T-cell therapy development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Precision BioSciences company profile →
Rubicon Genomics
HQ: United States
Website
- Description: Provider of advances in translating human genetics “laboratory knowledge” into practical medicine applications; founded in 2000 by University of Michigan faculty Dr. John Langmore and Dr. Vladimir Makarov, with roots in Michigan.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rubicon Genomics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Feldan Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Feldan Therapeutics
2.2 - Growth funds investing in similar companies to Feldan Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Feldan Therapeutics
4.2 - Public trading comparable groups for Feldan Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →